Poxel Announces Positive Top Line Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes May 4, 2017
Poxel to Present New Imeglimin Data at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes in Japan Apr 20, 2017
Poxel Announces Appointment of Christophe Arbet-Engels, MD, PhD, MBA, as Chief Medical Officer and EVP Late Development & Medical Affairs, Based in Boston Mar 7, 2017
Poxel Announces Phase 1 Initiation of EYP001 for the Treatment of Chronic Hepatitis B Virus Infection by Licensing Partner ENYO Pharma SA Dec 19, 2016
